Patients in the deferasirox 10 mg/kg/day starting dose group with baseline LIC >15 mg Fe/g dw had a greater reduction in LIC at Week 52 (−5.9 ± 5.3 mg Fe/g dw [ n = 20]) than those with baseline LIC >7 15 mg Fe/g dw (−2.6 ± 2.9 mg Fe/g dw [ n = 26]) or baseline LIC ≤7 mg Fe/g dw (−2.2 ± 1.3 mg Fe/g dw [ n = 8]).
Within the deferasirox arms, patients in the deferasirox 10 mg/kg/day starting dose group had better LIC responses than those in the deferasirox 5 mg/kg/day starting dose group (Fig. 1C).
The absolute difference of low fruit and vegetable consumption prevalence between poorest and richest adults of the study LIC group was near 10% (Men: 9.7%, 95% CI: 6.2, 13.2; Women: 9.5%, 95% CI: 6.5, 12.4).
Similar trends for inequality patterns were observed for women of MIC and LIC groups, but values did not reach statistical significance (Model 1).
Heavy episodic alcohol drinking data indicated mixed types of inequality, with reverse and regular inequalities among men of study MIC and LIC groups, respectively (prevalence difference: (MICs) -3.3%, 95% CI: -6.3, -0.3; (LICs) 2.7%, 95% CI: 1.2, 4.1).
In fact the 3 patients with hypogonadism in the present group all had high LIC values and had been transfused.
In the deferasirox core + extension group, absolute change in LIC by average actual dose category showed a dose response, with the highest decreases seen in the higher dose groups.
a R2-LIC versus biopsy LIC in 105 patients.
For the placebo/deferasirox group (n = 56), baseline LIC was 15.94 ± 10.85 mg Fe/g dw; at 1 year with placebo, mean LIC increased to 16.38 ± 10.43 mg Fe/g dw.
This predefined analysis evaluates deferasirox for maintaining LIC in patients with baseline LIC <7 mg Fe/g dw and for reducing LIC in those with baseline LIC ≥7 mg Fe/g dw.
